COVID-19 in patients with cancer: managing a pandemic within a pandemic von Horn, Leora, Garassino, Marina

Volltext

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer von Spigel, David R, Faivre-Finn, Corinne, Gray, Jhanelle E, Vicente, David, Planchard, David, Paz-Ares, Luis, Vansteenkiste, Johan F, Garassino, Marina C, Hui, Rina, Quantin, Xavier, Rimner, Andreas, Wu, Yi-Long, Özgüroğlu, Mustafa, Lee, Ki H, Kato, Terufumi, de Wit, Maike, Kurata, Takayasu, Reck, Martin, Cho, Byoung C, Senan, Suresh, Naidoo, Jarushka, Mann, Helen, Newton, Michael, Thiyagarajah, Piruntha, Antonia, Scott J

Volltext

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer von Gadgeel, Shirish, Rodríguez-Abreu, Delvys, Speranza, Giovanna, Esteban, Emilio, Felip, Enriqueta, Dómine, Manuel, Hui, Rina, Hochmair, Maximilian J, Clingan, Philip, Powell, Steven F, Cheng, Susanna Yee-Shan, Bischoff, Helge G, Peled, Nir, Grossi, Francesco, Jennens, Ross R, Reck, Martin, Garon, Edward B, Novello, Silvia, Rubio-Viqueira, Belén, Boyer, Michael, Kurata, Takayasu, Gray, Jhanelle E, Yang, Jing, Bas, Tuba, Pietanza, M Catherine, Garassino, Marina C

Volltext

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the... von Girard, Nicolas, Bar, Jair, Garrido, Pilar, Garassino, Marina C., McDonald, Fiona, Mornex, Françoise, Filippi, Andrea R., Smit, Hans J.M., Peters, Solange, Field, John K., Christoph, Daniel C., Sibille, Anne, Fietkau, Rainer, Haakensen, Vilde D., Chouaid, Christos, Markman, Ben, Hiltermann, T. Jeroen N., Taus, Alvaro, Sawyer, William, Allen, Allison, Chander, Pratibha, Licour, Muriel, Solomon, Benjamin

Volltext

Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial von Garassino, Marina C., Mazieres, Julien, Reck, Martin, Chouaid, Christos, Bischoff, Helge, Reinmuth, Niels, Cove-Smith, Laura, Mansy, Talal, Cortinovis, Diego, Migliorino, Maria R., Delmonte, Angelo, Sánchez, José Garcia, Chara Velarde, Luis Enrique, Bernabe, Reyes, Paz-Ares, Luis, Perez, Ignacio Diaz, Trunova, Nataliya, Foroutanpour, Kayhan, Faivre-Finn, Corinne

Volltext

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer von Mok, Tony S, Wu, Yi-Long, Ahn, Myung-Ju, Garassino, Marina C, Kim, Hye R, Ramalingam, Suresh S, Shepherd, Frances A, He, Yong, Akamatsu, Hiroaki, Theelen, Willemijn S.M.E, Lee, Chee K, Sebastian, Martin, Templeton, Alison, Mann, Helen, Marotti, Marcelo, Ghiorghiu, Serban, Papadimitrakopoulou, Vassiliki A

Volltext

Response to Letter to the Editor From Shaorong Yu and Jifeng Feng von Garassino, Marina C, Faivre-Finn, Corinne

Volltext

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study von Garassino, Marina C, Gadgeel, Shirish, Speranza, Giovanna, Felip, Enriqueta, Esteban, Emilio, Dómine, Manuel, Hochmair, Maximilian J, Powell, Steven F, Bischoff, Helge G, Peled, Nir, Grossi, Francesco, Jennens, Ross R, Reck, Martin, Hui, Rina, Garon, Edward B, Kurata, Takayasu, Gray, Jhanelle E, Schwarzenberger, Paul, Jensen, Erin, Pietanza, M Catherine, Rodríguez-Abreu, Delvys

Volltext

Response to Letter to the Editor From Binghao Zhao et al von Girard, Nicolas, Garassino, Marina C., Solomon, Benjamin

Volltext

Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial von Faivre-Finn, Corinne, Vicente, David, Kurata, Takayasu, Planchard, David, Paz-Ares, Luis, Vansteenkiste, Johan F., Spigel, David R., Garassino, Marina C., Reck, Martin, Senan, Suresh, Naidoo, Jarushka, Rimner, Andreas, Wu, Yi-Long, Gray, Jhanelle E., Özgüroğlu, Mustafa, Lee, Ki H., Cho, Byoung C., Kato, Terufumi, de Wit, Maike, Newton, Michael, Wang, Lu, Thiyagarajah, Piruntha, Antonia, Scott J.

Volltext

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer von Gandhi, Leena, Rodríguez-Abreu, Delvys, Gadgeel, Shirish, Esteban, Emilio, Felip, Enriqueta, De Angelis, Flávia, Domine, Manuel, Clingan, Philip, Hochmair, Maximilian J, Powell, Steven F, Cheng, Susanna Y.-S, Bischoff, Helge G, Peled, Nir, Grossi, Francesco, Jennens, Ross R, Reck, Martin, Hui, Rina, Garon, Edward B, Boyer, Michael, Rubio-Viqueira, Belén, Novello, Silvia, Kurata, Takayasu, Gray, Jhanelle E, Vida, John, Wei, Ziwen, Yang, Jing, Raftopoulos, Harry, Pietanza, M. Catherine, Garassino, Marina C

Volltext

Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer... von Garassino, Marina C, Gadgeel, Shirish, Esteban, Emilio, Felip, Enriqueta, Speranza, Giovanna, Domine, Manuel, Hochmair, Maximilian J, Powell, Steven, Cheng, Susanna Yee-Shan, Bischoff, Helge G, Peled, Nir, Reck, Martin, Hui, Rina, Garon, Edward B, Boyer, Michael, Wei, Ziwen, Burke, Thomas, Pietanza, M Catherine, Rodríguez-Abreu, Delvys

Volltext

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer von Brahmer, Julie, Reckamp, Karen L, Baas, Paul, Crinò, Lucio, Eberhardt, Wilfried E.E, Poddubskaya, Elena, Antonia, Scott, Pluzanski, Adam, Vokes, Everett E, Holgado, Esther, Waterhouse, David, Ready, Neal, Gainor, Justin, Arén Frontera, Osvaldo, Havel, Libor, Steins, Martin, Garassino, Marina C, Aerts, Joachim G, Domine, Manuel, Paz-Ares, Luis, Reck, Martin, Baudelet, Christine, Harbison, Christopher T, Lestini, Brian, Spigel, David R

Volltext

Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-a... von Viscardi, Giuseppe, Tralongo, Antonino C., Massari, Francesco, Lambertini, Matteo, Mollica, Veronica, Rizzo, Alessandro, Comito, Francesca, Di Liello, Raimondo, Alfieri, Salvatore, Imbimbo, Martina, Della Corte, Carminia M., Morgillo, Floriana, Simeon, Vittorio, Lo Russo, Giuseppe, Proto, Claudia, Prelaj, Arsela, De Toma, Alessandro, Galli, Giulia, Signorelli, Diego, Ciardiello, Fortunato, Remon, Jordi, Chaput, Nathalie, Besse, Benjamin, de Braud, Filippo, Garassino, Marina C., Torri, Valter, Cinquini, Michela, Ferrara, Roberto

Volltext

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations von Paik, Paul K, Felip, Enriqueta, Veillon, Remi, Sakai, Hiroshi, Cortot, Alexis B, Garassino, Marina C, Mazieres, Julien, Viteri, Santiago, Senellart, Helene, Van Meerbeeck, Jan, Raskin, Jo, Reinmuth, Niels, Conte, Pierfranco, Kowalski, Dariusz, Cho, Byoung Chul, Patel, Jyoti D, Horn, Leora, Griesinger, Frank, Han, Ji-Youn, Kim, Young-Chul, Chang, Gee-Chen, Tsai, Chen-Liang, Yang, James C.-H, Chen, Yuh-Min, Smit, Egbert F, van der Wekken, Anthonie J, Kato, Terufumi, Juraeva, Dilafruz, Stroh, Christopher, Bruns, Rolf, Straub, Josef, Johne, Andreas, Scheele, Jürgen, Heymach, John V, Le, Xiuning

Volltext

Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy von Ferrara, Roberto, Naigeon, Marie, Auclin, Edouard, Duchemann, Boris, Cassard, Lydie, Jouniaux, Jean-Mehdi, Boselli, Lisa, Grivel, Jonathan, Desnoyer, Aude, Mezquita, Laura, Texier, Matthieu, Caramella, Caroline, Hendriks, Lizza, Planchard, David, Remon, Jordi, Sangaletti, Sabina, Proto, Claudia, Garassino, Marina C, Soria, Jean-Charles, Marabelle, Aurelien, Voisin, Anne-Laure, Farhane, Siham, Besse, Benjamin, Chaput, Nathalie

Volltext

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH) von Peters, Solange, Gettinger, Scott, Johnson, Melissa L, Jänne, Pasi A, Garassino, Marina C, Christoph, Daniel, Toh, Chee Keong, Rizvi, Naiyer A, Chaft, Jamie E, Carcereny Costa, Enric, Patel, Jyoti D, Chow, Laura Q M, Koczywas, Marianna, Ho, Cheryl, Früh, Martin, van den Heuvel, Michel, Rothenstein, Jeffrey, Reck, Martin, Paz-Ares, Luis, Shepherd, Frances A, Kurata, Takayasu, Li, Zhengrong, Qiu, Jiaheng, Kowanetz, Marcin, Mocci, Simonetta, Shankar, Geetha, Sandler, Alan, Felip, Enriqueta

Volltext

Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program von Prelaj, Arsela, Bottiglieri, Achille, Proto, Claudia, Lo Russo, Giuseppe, Signorelli, Diego, Ferrara, Roberto, Galli, Giulia, De Toma, Alessandro, Viscardi, Giuseppe, Brambilla, Marta, Lobefaro, Riccardo, Nichetti, Federico, Manglaviti, Sara, Occhipinti, Mario, Labianca, Alice, Ganzinelli, Monica, Gallucci, Rosaria, Zilembo, Nicoletta, Greco, Gabriella Francesca, Torri, Valter, de Braud, Filippo, Garassino, Marina C.

Volltext

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized con... von Borghaei, Hossein, Langer, Corey J., Paz‐Ares, Luis, Rodríguez‐Abreu, Delvys, Halmos, Balazs, Garassino, Marina C., Houghton, Baerin, Kurata, Takayasu, Cheng, Ying, Lin, Jianxin, Pietanza, M. Catherine, Piperdi, Bilal, Gadgeel, Shirish M.

Volltext

Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer von Crinò, Lucio, Bronte, Giuseppe, Bidoli, Paolo, Cravero, Paola, Minenza, Elisa, Cortesi, Enrico, Garassino, Marina C., Proto, Claudia, Cappuzzo, Federico, Grossi, Francesco, Tonini, Giuseppe, Sarobba, Maria Giuseppina, Pinotti, Graziella, Numico, Gianmauro, Samaritani, Riccardo, Ciuffreda, Libero, Frassoldati, Antonio, Bregni, Marco, Santo, Antonio, Piantedosi, Francovito, Illiano, Alfonso, De Marinis, Filippo, Tamberi, Stefano, Giannarelli, Diana, Delmonte, Angelo

Volltext